JPWO2022010537A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022010537A5 JPWO2022010537A5 JP2023501137A JP2023501137A JPWO2022010537A5 JP WO2022010537 A5 JPWO2022010537 A5 JP WO2022010537A5 JP 2023501137 A JP2023501137 A JP 2023501137A JP 2023501137 A JP2023501137 A JP 2023501137A JP WO2022010537 A5 JPWO2022010537 A5 JP WO2022010537A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutically acceptable
- heteroaryl
- acceptable salt
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 31
- 150000003839 salts Chemical class 0.000 claims 24
- 125000003118 aryl group Chemical group 0.000 claims 17
- 125000001072 heteroaryl group Chemical group 0.000 claims 17
- 125000000623 heterocyclic group Chemical group 0.000 claims 15
- 125000000753 cycloalkyl group Chemical group 0.000 claims 11
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 239000001257 hydrogen Substances 0.000 claims 9
- -1 cyano, sulfonyl Chemical group 0.000 claims 8
- 125000003710 aryl alkyl group Chemical group 0.000 claims 6
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 6
- 239000008194 pharmaceutical composition Substances 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000001188 haloalkyl group Chemical group 0.000 claims 5
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 5
- 238000000034 method Methods 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims 4
- 125000002252 acyl group Chemical group 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 4
- 125000003368 amide group Chemical group 0.000 claims 4
- 125000004103 aminoalkyl group Chemical group 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 125000000304 alkynyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 3
- 125000004404 heteroalkyl group Chemical group 0.000 claims 3
- 125000005842 heteroatom Chemical group 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical group C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical class 0.000 claims 2
- 125000004001 thioalkyl group Chemical group 0.000 claims 2
- 229930192474 thiophene Natural products 0.000 claims 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 1
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 1
- 206010003571 Astrocytoma Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010039491 Sarcoma Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims 1
- 102100024780 YEATS domain-containing protein 4 Human genes 0.000 claims 1
- 101710107170 YEATS domain-containing protein 4 Proteins 0.000 claims 1
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 1
- 125000000278 alkyl amino alkyl group Chemical group 0.000 claims 1
- 125000003282 alkyl amino group Chemical group 0.000 claims 1
- 125000001769 aryl amino group Chemical group 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 239000004202 carbamide Substances 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000004181 carboxyalkyl group Chemical group 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 claims 1
- 125000004663 dialkyl amino group Chemical group 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 208000005017 glioblastoma Diseases 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 238000007911 parenteral administration Methods 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Claims (28)
またはその薬学的に許容される塩であって、式中、
R1が、ヘテロシクリル、ヘテロシクリルアルキル、ヘテロアリール、ヘテロアリールアルキル、アリール、アリールアルキル、シクロアルキル、シクロアルキルアルキル、アルキル、アルケニル、アルキニル、ヒドロキシ、アルコキシ、チオアルキル、ハロゲン、ハロアルキル、カルボキシ、アシル、アミド、シアノ、スルホニル及び水素から選択されており、
Xが、-C(O)-、-C(S)-、-CH2-もしくは-SO2-であるか、または存在せず、
Yが、-NRa-または-O-であり、
Raが、水素、アルキル、ハロアルキル、ヘテロアルキル、シクロアルキル、ヒドロキシアルキル及びアミノアルキルから選択されているか、もしくはRaが、そのRaと結合している窒素原子と一体となって、Aとの縮合環を形成するか、またはRa及びR1が、それらと結合している原子と一体となって、任意に置換された複素環式環を形成し、
Zが、存在しないか、または-CRbRc-であり、
Rb及びRcがそれぞれ独立して、水素及びアルキルから選択されており、
Aが、5員のヘテロアリールであり、
Qが、4員、5員または6員のヘテロシクリルであり、
R2が、水素、ハロ、アルキル、アミノ及びヒドロキシから選択されており、
R3が、水素、ハロ、-ORd、-NReRf、アリール、アリールアルキル、ヘテロアリール、ヘテロアリールアルキル、ヘテロシクリル、ヘテロシクリルアルキル及び下記の式の基から選択されており、
式中、Bが、アリールまたはヘテロアリールであり、Jが、存在しないか、または-CH2-、-O-、-S-もしくは-NH-であり、Cが、アリール、ヘテロアリール及びヘテロシクリルから選択されており、mが、0、1、2、3または4であり、nが、0、1、2、3、4または5であり、Rg及びRhがそれぞれ独立して、アルキル、アルケニル、アルキニル、ハロ、ハロアルキル、アミノ、アルキルアミノ、ジアルキルアミノ、アミノアルキル、アルキルアミノアルキル、ジアルキルアミノアルキル、アミド、アミドアルキル、スルホンアミド、スルホンアミドアルキル、尿素、尿素アルキル、チオ尿素、チオ尿素アルキル、ヒドロキシ、ヒドロキシアルキル、アルコキシ、アルコキシアルキル、ハロアルコキシ、チオアルキル、アシル、カルボキシ、ニトロ、オキソ、アリール、アリールアルキル、ヘテロアリール、ヘテロアリールアルキル、ヘテロシクリル、ヘテロシクリルアルキル、シクロアルキル及びシクロアルキルアルキルから選択されているか、
あるいは、R2及びR3が、それらと結合している炭素原子(複数可)と一体となって、アリール、ヘテロアリール、シクロアルキル及び複素環から選択される環を形成するか、またはR2及びR3が、それらと結合している炭素原子と一体となって、アルケニル基を形成し、
Rd、Re及びRfがそれぞれ独立して、水素、アルキル、ハロアルキル、ヒドロキシアルキル、アミノアルキル、カルボキシアルキル、ヘテロアルキル、アリール、アリールアルキル、ヘテロアリール、ヘテロアリールアルキルから選択されており、
それぞれのアルキル、アルケニル、アルキニル、アリール、アリールアルキル、ヘテロアルキル、ヘテロアリール、ヘテロアリールアルキル、シクロアルキル、ヘテロシクリル及びヘテロシクリルアルキルが独立して、1個、2個、3個、4個または5個の置換基で任意に置換されており、
ただし、Zが、-CRbRc-であるときには、R1が、シクロアルキルではない、前記化合物または前記塩。 A compound of formula (I) below,
or a pharmaceutically acceptable salt thereof, in which:
R 1 is heterocyclyl, heterocyclylalkyl, heteroaryl, heteroarylalkyl, aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, alkyl, alkenyl, alkynyl, hydroxy, alkoxy, thioalkyl, halogen, haloalkyl, carboxy, acyl, amido, selected from cyano, sulfonyl and hydrogen;
X is -C(O)-, -C(S)-, -CH2- or -SO2- , or is absent;
Y is -NR a - or -O-,
R a is selected from hydrogen, alkyl, haloalkyl, heteroalkyl, cycloalkyl , hydroxyalkyl and aminoalkyl, or R a is combined with the nitrogen atom to which it is bonded, or R a and R 1 together with the atoms to which they are bonded form an optionally substituted heterocyclic ring;
Z is absent or -CR b R c -,
R b and R c are each independently selected from hydrogen and alkyl;
A is a 5-membered heteroaryl,
Q is 4-, 5- or 6-membered heterocyclyl,
R 2 is selected from hydrogen, halo, alkyl, amino and hydroxy;
R 3 is selected from hydrogen, halo, -OR d , -NR e R f , aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, and groups of the formula:
where B is aryl or heteroaryl, J is absent or -CH 2 -, -O-, -S- or -NH-, and C is selected from aryl, heteroaryl and heterocyclyl and m is 0, 1, 2, 3 or 4, n is 0, 1, 2, 3, 4 or 5, and R g and R h are each independently alkyl, Alkenyl, alkynyl, halo, haloalkyl, amino, alkylamino, dialkylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, amido, amidoalkyl, sulfonamide, sulfonamidoalkyl, urea, ureaalkyl, thiourea, thioureaalkyl , hydroxy, hydroxyalkyl, alkoxy, alkoxyalkyl, haloalkoxy, thioalkyl, acyl, carboxy, nitro, oxo, aryl, arylalkyl, heteroaryl, heteroarylalkyl, heterocyclyl, heterocyclylalkyl, cycloalkyl and cycloalkylalkyl. Are you there?
Alternatively, R 2 and R 3 together with the carbon atom(s) to which they are attached form a ring selected from aryl, heteroaryl, cycloalkyl and heterocycle, or R 2 and R 3 together with the carbon atoms bonded thereto form an alkenyl group,
R d , R e and R f are each independently selected from hydrogen, alkyl, haloalkyl, hydroxyalkyl, aminoalkyl, carboxyalkyl, heteroalkyl, aryl, arylalkyl, heteroaryl, heteroarylalkyl;
Each alkyl, alkenyl, alkynyl, aryl, arylalkyl, heteroalkyl, heteroaryl, heteroarylalkyl, cycloalkyl, heterocyclyl and heterocyclylalkyl independently represents 1, 2, 3, 4 or 5 is optionally substituted with a substituent,
However, when Z is -CR b R c -, the compound or the salt in which R 1 is not cycloalkyl.
という基が、
から選択される式を有し、
式中、Rx、Ry及びRzが、それぞれ独立して-ORv、アリール及びヘテロアリールから選択されている置換基であり、Rvが、C1-C6アルキル、アリール及びヘテロアリールから選択されている、請求項1~15のいずれか1項に記載の化合物またはその薬学的に許容される塩。
The basis is
has a formula selected from
where R x , R y and R z are each independently a substituent selected from -OR v , aryl and heteroaryl, and R v is C 1 -C 6 alkyl, aryl and heteroaryl. A compound according to any one of claims 1 to 15, selected from: or a pharmaceutically acceptable salt thereof.
式中、
nが、0、1、2または3であり、
それぞれのRhが独立して、C1-C6アルキル、ハロ、ハロ-C1-C6アルキル、アミノ、アミノ-C1-C6アルキル、ヒドロキシ、ヒドロキシ-C1-C6アルキル、C1-C6アルコキシ、アミド、アミド-C1-C6アルキル、アシル、アリール、アリール-C1-C6アルキル、ヘテロアリール、ヘテロアリール-C1-C6アルキル、ヘテロシクリル、ヘテロシクリル-C1-C6アルキル、シクロアルキル及びシクロアルキル-C1-C6アルキルから選択されている、請求項1に記載の化合物またはその薬学的に許容される塩。 The compound has the following formula (Ic),
During the ceremony,
n is 0, 1, 2 or 3,
Each R h is independently C 1 -C 6 alkyl, halo, halo-C 1 -C 6 alkyl, amino, amino-C 1 -C 6 alkyl, hydroxy, hydroxy-C 1 -C 6 alkyl, C 1 - C6 alkoxy, amido, amido- C1 - C6 alkyl, acyl, aryl , aryl-C1-C6 alkyl, heteroaryl, heteroaryl - C1 - C6 alkyl, heterocyclyl, heterocyclyl- C1- 2. A compound according to claim 1, or a pharmaceutically acceptable salt thereof, selected from C 6 alkyl, cycloalkyl and cycloalkyl-C 1 -C 6 alkyl.
r及びsがそれぞれ独立して、0、1及び2から選択されており、
Ri及びRkがそれぞれ独立して、水素及びC1-C6アルキルから選択されており、
Rjが、C1-C6アルキル、アリール、アリール-C1-C6アルキル、ヘテロアリール、ヘテロアリール-C1-C6アルキル、ヘテロシクリル、ヘテロシクリル-C1-C6アルキル、シクロアルキル及びシクロアルキル-C1-C6アルキルから選択されており、
Rmが、C1-C6アルキル、アリール、アリール-C1-C6アルキル、ヘテロアリール、ヘテロアリール-C1-C6アルキル、ヘテロシクリル、ヘテロシクリル-C1-C6アルキル、シクロアルキル及びシクロアルキル-C1-C6アルキル、アミノ、C1-C6アルキルアミノ、アリールアミノ及びアリール-C1-C6アルキルアミノから選択されており、
それぞれのアルキル、アリール、ヘテロアリール、ヘテロシクリル及びシクロアルキルが独立して、非置換であるか、または独立してハロ、C1-C6アルキル、C1-C6-アルコキシ、ヒドロキシ、アミノ及びオキソから選択される1個もしくは2個の置換基で置換されている、請求項1~20のいずれか1項に記載の化合物またはその薬学的に許容される塩。 At least one R h has the formula -(CH 2 ) r C(O)NR i R j or -(CH 2 ) s NR k C(O)R m , where
r and s are each independently selected from 0, 1 and 2,
R i and R k are each independently selected from hydrogen and C 1 -C 6 alkyl;
R j is C 1 -C 6 alkyl, aryl, aryl-C 1 -C 6 alkyl, heteroaryl, heteroaryl-C 1 -C 6 alkyl, heterocyclyl, heterocyclyl-C 1 -C 6 alkyl, cycloalkyl and cyclo selected from alkyl-C 1 -C 6 alkyl;
R m is C 1 -C 6 alkyl, aryl, aryl-C 1 -C 6 alkyl, heteroaryl, heteroaryl-C 1 -C 6 alkyl, heterocyclyl, heterocyclyl-C 1 -C 6 alkyl, cycloalkyl and cyclo selected from alkyl-C 1 -C 6 alkyl, amino, C 1 -C 6 alkylamino, arylamino and aryl-C 1 -C 6 alkylamino,
Each alkyl, aryl, heteroaryl, heterocyclyl and cycloalkyl is independently unsubstituted or independently halo, C 1 -C 6 alkyl, C 1 -C 6 -alkoxy, hydroxy, amino and oxo The compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt thereof, which is substituted with one or two substituents selected from.
A compound according to any one of claims 1 to 21 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to any one of claims 22 to 24 for the treatment of cancer. use.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063050303P | 2020-07-10 | 2020-07-10 | |
US63/050,303 | 2020-07-10 | ||
PCT/US2021/015263 WO2022010537A1 (en) | 2020-07-10 | 2021-01-27 | Gas41 inhibitors and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023533982A JP2023533982A (en) | 2023-08-07 |
JPWO2022010537A5 true JPWO2022010537A5 (en) | 2024-02-02 |
Family
ID=79291969
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2023501137A Pending JP2023533982A (en) | 2020-07-10 | 2021-01-27 | GAS41 inhibitor and method of use thereof |
Country Status (7)
Country | Link |
---|---|
US (1) | US11858925B2 (en) |
EP (1) | EP4178571A1 (en) |
JP (1) | JP2023533982A (en) |
CN (1) | CN116113406A (en) |
AU (1) | AU2021304826A1 (en) |
CA (1) | CA3185209A1 (en) |
WO (1) | WO2022010537A1 (en) |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3598122A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3993073A (en) | 1969-04-01 | 1976-11-23 | Alza Corporation | Novel drug delivery device |
US3710795A (en) | 1970-09-29 | 1973-01-16 | Alza Corp | Drug-delivery device with stretched, rate-controlling membrane |
US4069307A (en) | 1970-10-01 | 1978-01-17 | Alza Corporation | Drug-delivery device comprising certain polymeric materials for controlled release of drug |
US3731683A (en) | 1971-06-04 | 1973-05-08 | Alza Corp | Bandage for the controlled metering of topical drugs to the skin |
US3742951A (en) | 1971-08-09 | 1973-07-03 | Alza Corp | Bandage for controlled release of vasodilators |
US3996934A (en) | 1971-08-09 | 1976-12-14 | Alza Corporation | Medical bandage |
BE795384A (en) | 1972-02-14 | 1973-08-13 | Ici Ltd | DRESSINGS |
US3921636A (en) | 1973-01-15 | 1975-11-25 | Alza Corp | Novel drug delivery device |
US3993072A (en) | 1974-08-28 | 1976-11-23 | Alza Corporation | Microporous drug delivery device |
US4151273A (en) | 1974-10-31 | 1979-04-24 | The Regents Of The University Of California | Increasing the absorption rate of insoluble drugs |
US3972995A (en) | 1975-04-14 | 1976-08-03 | American Home Products Corporation | Dosage form |
US4077407A (en) | 1975-11-24 | 1978-03-07 | Alza Corporation | Osmotic devices having composite walls |
US4031894A (en) | 1975-12-08 | 1977-06-28 | Alza Corporation | Bandage for transdermally administering scopolamine to prevent nausea |
US4060084A (en) | 1976-09-07 | 1977-11-29 | Alza Corporation | Method and therapeutic system for providing chemotherapy transdermally |
US4201211A (en) | 1977-07-12 | 1980-05-06 | Alza Corporation | Therapeutic system for administering clonidine transdermally |
JPS5562012A (en) | 1978-11-06 | 1980-05-10 | Teijin Ltd | Slow-releasing preparation |
US4230105A (en) | 1978-11-13 | 1980-10-28 | Merck & Co., Inc. | Transdermal delivery of drugs |
US4229447A (en) | 1979-06-04 | 1980-10-21 | American Home Products Corporation | Intraoral methods of using benzodiazepines |
CA1146866A (en) | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
US4291015A (en) | 1979-08-14 | 1981-09-22 | Key Pharmaceuticals, Inc. | Polymeric diffusion matrix containing a vasodilator |
US5116817A (en) | 1982-12-10 | 1992-05-26 | Syntex (U.S.A.) Inc. | LHRH preparations for intranasal administration |
US4476116A (en) | 1982-12-10 | 1984-10-09 | Syntex (U.S.A.) Inc. | Polypeptides/chelating agent nasal compositions having enhanced peptide absorption |
US4596795A (en) | 1984-04-25 | 1986-06-24 | The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services | Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives |
US4755386A (en) | 1986-01-22 | 1988-07-05 | Schering Corporation | Buccal formulation |
US5312325A (en) | 1987-05-28 | 1994-05-17 | Drug Delivery Systems Inc | Pulsating transdermal drug delivery system |
US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
GB8827305D0 (en) | 1988-11-23 | 1988-12-29 | British Bio Technology | Compounds |
US5739136A (en) | 1989-10-17 | 1998-04-14 | Ellinwood, Jr.; Everett H. | Intraoral dosing method of administering medicaments |
US5633009A (en) | 1990-11-28 | 1997-05-27 | Sano Corporation | Transdermal administration of azapirones |
DK0580860T4 (en) | 1991-04-16 | 2005-03-21 | Nippon Shinyaku Co Ltd | Process for preparing a solid dispersion |
US5340591A (en) | 1992-01-24 | 1994-08-23 | Fujisawa Pharmaceutical Co., Ltd. | Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine |
US5281420A (en) | 1992-05-19 | 1994-01-25 | The Procter & Gamble Company | Solid dispersion compositions of tebufelone |
US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
AU4198793A (en) | 1992-07-24 | 1994-01-27 | Takeda Chemical Industries Ltd. | Microparticle preparation and production thereof |
US5700485A (en) | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
US5455258A (en) | 1993-01-06 | 1995-10-03 | Ciba-Geigy Corporation | Arylsulfonamido-substituted hydroxamic acids |
DE69430861T2 (en) * | 1993-04-07 | 2003-01-23 | Otsuka Pharma Co Ltd | N-ACYLATED 4-AMINOPIPERIDINE DERIVATIVES AS ACTIVE INGREDIENTS OF PERIPHERAL VESSEL WIDING AGENTS |
US5665378A (en) | 1994-09-30 | 1997-09-09 | Davis; Roosevelt | Transdermal therapeutic formulation |
US5863949A (en) | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
WO1996033172A1 (en) | 1995-04-20 | 1996-10-24 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives as mmp and tnf inhibitors |
SE9502244D0 (en) | 1995-06-20 | 1995-06-20 | Bioglan Ab | A composition and a process for the preparation thereof |
EP0780386B1 (en) | 1995-12-20 | 2002-10-02 | F. Hoffmann-La Roche Ag | Matrix metalloprotease inhibitors |
US5858401A (en) | 1996-01-22 | 1999-01-12 | Sidmak Laboratories, Inc. | Pharmaceutical composition for cyclosporines |
US6923983B2 (en) | 1996-02-19 | 2005-08-02 | Acrux Dds Pty Ltd | Transdermal delivery of hormones |
US6929801B2 (en) | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
EP0818442A3 (en) | 1996-07-12 | 1998-12-30 | Pfizer Inc. | Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor |
EP0923585B1 (en) | 1996-07-18 | 2002-05-08 | Pfizer Inc. | Phosphinate based inhibitors of matrix metalloproteases |
SK21499A3 (en) | 1996-08-23 | 2000-05-16 | Pfizer | Arylsulfonylamino hydroxamic acid derivatives |
BR9714266A (en) | 1997-01-06 | 2000-04-18 | Pfizer | Cyclic sulfone derivatives. |
US6458373B1 (en) | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
PL335027A1 (en) | 1997-02-03 | 2000-03-27 | Pfizer Prod Inc | Derivatives of arylsulphonylamino hydroxamic acid |
AU5493598A (en) | 1997-02-07 | 1998-08-26 | Pfizer Inc. | N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases |
AU722784B2 (en) | 1997-02-11 | 2000-08-10 | Pfizer Inc. | Arylsulfonyl hydroxamic acid derivatives |
US6391452B1 (en) | 1997-07-18 | 2002-05-21 | Bayer Corporation | Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations |
CA2299355C (en) | 1997-08-08 | 2005-09-27 | Pfizer Products Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
GB9725782D0 (en) | 1997-12-05 | 1998-02-04 | Pfizer Ltd | Therapeutic agents |
US5869090A (en) | 1998-01-20 | 1999-02-09 | Rosenbaum; Jerry | Transdermal delivery of dehydroepiandrosterone |
GB9801690D0 (en) | 1998-01-27 | 1998-03-25 | Pfizer Ltd | Therapeutic agents |
PA8469401A1 (en) | 1998-04-10 | 2000-05-24 | Pfizer Prod Inc | BICYCLE DERIVATIVES OF HYDROXAMIC ACID |
PA8469501A1 (en) | 1998-04-10 | 2000-09-29 | Pfizer Prod Inc | HYDROXAMIDES OF THE ACID (4-ARILSULFONILAMINO) -TETRAHIDROPIRAN-4-CARBOXILICO |
US6946144B1 (en) | 1998-07-08 | 2005-09-20 | Oryxe | Transdermal delivery system |
DE69915004T2 (en) | 1998-11-05 | 2004-09-09 | Pfizer Products Inc., Groton | 5-Oxo-pyrrolidine-2-carboxylic acid Hydroxamidderivate |
ES2307482T3 (en) | 1999-02-10 | 2008-12-01 | Pfizer Products Inc. | SOLID PHARMACEUTICAL DISPERSIONS. |
WO2000071508A2 (en) | 1999-05-24 | 2000-11-30 | Cor Therapeutics, Inc. | INHIBITORS OF FACTOR Xa |
GB9912961D0 (en) | 1999-06-03 | 1999-08-04 | Pfizer Ltd | Metalloprotease inhibitors |
EP1081137A1 (en) | 1999-08-12 | 2001-03-07 | Pfizer Products Inc. | Selective inhibitors of aggrecanase in osteoarthritis treatment |
IL149701A0 (en) | 2001-05-23 | 2002-11-10 | Pfizer Prod Inc | Use of anti-ctla-4 antibodies |
US6960563B2 (en) | 2001-08-31 | 2005-11-01 | Morton Grove Pharmaceuticals, Inc. | Spontaneous emulsions containing cyclosporine |
NZ550796A (en) | 2004-05-06 | 2010-07-30 | Warner Lambert Co | 4-phenylamino-quinazolin-6-yl-amides |
MX2008002364A (en) | 2005-08-17 | 2008-03-18 | Schering Corp | Novel high affinity thiophene-based and furan-based kinase ligands. |
RS59494B1 (en) | 2010-02-12 | 2019-12-31 | Pfizer | Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one |
EP3404021A4 (en) | 2016-01-12 | 2019-09-11 | Nippon Chemiphar Co., Ltd. | Voltage-dependent t-type calcium channel inhibitor |
-
2021
- 2021-01-27 JP JP2023501137A patent/JP2023533982A/en active Pending
- 2021-01-27 US US17/159,916 patent/US11858925B2/en active Active
- 2021-01-27 CN CN202180062307.2A patent/CN116113406A/en active Pending
- 2021-01-27 WO PCT/US2021/015263 patent/WO2022010537A1/en unknown
- 2021-01-27 CA CA3185209A patent/CA3185209A1/en active Pending
- 2021-01-27 AU AU2021304826A patent/AU2021304826A1/en active Pending
- 2021-01-27 EP EP21837808.1A patent/EP4178571A1/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2403253C2 (en) | Purine derivatives for application as agonists of adenosine receptor a-2a | |
JP2020511454A5 (en) | ||
RU2009115784A (en) | Pyrazole [1,5-A] pyrimidine derivatives and their use in medicine | |
RU2008112691A (en) | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND ITS PHARMACEUTICAL APPLICATION | |
RU2008119842A (en) | TRIAZOLE DERIVATIVES AS 11-BETA-HYDROXISTEROID-DEHYDROHENASE-1 INHIBITORS | |
JP2007517044A5 (en) | ||
JP2005538100A5 (en) | ||
JP2010501478A5 (en) | ||
JP2007517035A5 (en) | ||
RU2013143028A (en) | Thiazolylphenylbenzenesulfonamide derivatives as kinase inhibitors | |
RU2009144538A (en) | NEW CYCLIC PEPTIDE COMPOUNDS | |
JP2005535586A5 (en) | ||
RU2008136187A (en) | NEW CUMARIN DERIVATIVE WITH ANTITUMOR ACTIVITY | |
RU2006112593A (en) | 2, 4-DI (HETERO) ARILAMINOPYRIMIDINE DERIVATIVES AS ZAP-70 AND / OR SYK INHIBITORS | |
JP2010513322A5 (en) | ||
JP2007512349A5 (en) | ||
KR940021063A (en) | Quinolonecarboxylic acid derivatives, preparation method and use thereof | |
RU2010126105A (en) | Pyridine derivatives substituted by a heterocyclic ring and a phosphonoxymethyl group and containing antifungal agents | |
HUP0300416A2 (en) | Oxazolidinone derivatives with antibiotic activity, process for their preparation, their use and pharmaceutical compositions containing them | |
JP2005537323A5 (en) | ||
RU2007108863A (en) | Pyrazole derivatives for the treatment of conditions mediated by activation of an adenosine A2B or A3 receptor | |
CA2572208A1 (en) | 3-carbamoyl-2-pyridone derivative | |
RU2007111711A (en) | TRICYCLIC LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXISTEROID DEHYDROGENASE | |
RU2006110186A (en) | ALCOXY SUBSTITUTED IMIDAZOCHINOLINS | |
RU2007130144A (en) | HETEROCYCLIC COMPOUNDS AS CCCR2B ANTAGONISTS |